1-cyclohexyl-1-hydroxy-2-butanone | 99309-95-2

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1-cyclohexyl-1-hydroxy-2-butanone
• 英文别名: 1-Cyclohexyl-1-hydroxybutan-2-one
• CAS: 99309-95-2
• 化学式: C₁₀H₁₈O₂
• 分子量: 170.252
• InChiKey: IRFFVYFFRRLKOF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  12
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.9
• 拓扑面积：
  37.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  α-<(E)-1-methoxypropenyl>cyclohexanemethanol 在 盐酸 作用下， 反应 16.0h， 生成 1-cyclohexyl-1-hydroxy-2-butanone
  参考文献：
  名称：

  Alkylation-reduction of carbonyl systems. Part 14. Tandem alkylation-reduction. Highly stereoselective synthesis of (E)-1-hydroxymethyl methyl propenyl ethers from aldehydes using 1-lithio-1-methoxyallene

  摘要：

  DOI：

  10.1021/jo00225a061

文献信息

• 4-AMINO-4-OXOBUTANOYL PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20090048297A1

  公开（公告）日：2009-02-19

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R 1 -R 9 , R 16 , R 18 , R 19 , n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.

  该发明提供了Formula I的4-氨基-4-氧代丁酰肽化合物及其药用盐和水合物。变量R1-R9、R16、R18、R19、n、M和Z在此处定义。Formula I的某些化合物可用作抗病毒剂。本文披露的某些4-氨基-4-氧代丁酰肽化合物是有效和/或选择性抑制病毒复制的药物，特别是乙型肝炎病毒的复制。该发明还提供含有一种或多种4-氨基-4-氧代丁酰肽化合物和一种或多种药用载体的药物组合物。这种药物组合物可能仅含有4-氨基-4-氧代丁酰肽化合物作为唯一活性剂，也可能含有一种或多种其他药用活性剂与含有4-氨基-4-氧代丁酰肽的肽化合物的组合。该发明还提供了治疗哺乳动物病毒感染的方法，包括乙型肝炎感染。
• Nucleophilic acylation of esters by acid chlorides mediated by samarium diiodide: Formation and use of samarium enediolates
  作者：Fouzia Machrouhi、Jean-Louis Namy、Henri B. Kagan

  DOI：10.1016/s0040-4039(97)01727-9

  日期：1997.10

  Acid chlorides react with esters in the presence of samarium diiodide and catalytic amounts of NiI2 to afford samarium enediolates which can further react with electrophiles such as water or aldehydes to give respectively alpha-ketols or alpha-dihydroxyketones. (C) 1997 Published by Elsevier Science Ltd.
• WEIBERTH, F. J.;HALL, S. S., J. ORG. CHEM., 1985, 50, N 25, 5308-5314
  作者：WEIBERTH, F. J.、HALL, S. S.

  DOI：——

  日期：——
• MACROCYCLIC PEPTIDES AS INHIBITORS OF VIRAL REPLICATION
  申请人：Phadke Avinash

  公开号：US20110070168A1

  公开（公告）日：2011-03-24

  The invention provides 4-amino-4-oxobutanoyl peptide compounds of Formula I and the pharmaceutically salts and hydrates thereof. The variables R 1 -R 9 , R 16 , R 18 , R 19 , n, M, n, M, and Z are defined herein. Certain compounds of Formula I are useful as antiviral agents. Certain 4-amino-4-oxobutanoyl peptide compounds disclosed herein are potent and/or selective inhibitors of viral replication, particularly Hepatitis C virus replication. The invention also provides pharmaceutical compositions containing one or more 4-amino-4-oxobutanoyl peptide compounds and one or more pharmaceutically acceptable carriers. Such pharmaceutical compositions may contain 4-amino-4-oxobutanoyl peptide compound as the only active agent or may contain a combination of 4-amino-4-oxobutanoyl peptide containing peptides compound and one or more other pharmaceutically active agents. The invention also provides methods for treating viral infections, including Hepatitis C infections, in mammals.
• US7906619B2
  申请人：——

  公开号：US7906619B2

  公开（公告）日：2011-03-15